Michmerhuizen, Anna R. http://orcid.org/0000-0003-1105-287X
Lerner, Lynn M.
Pesch, Andrea M. http://orcid.org/0000-0003-0228-8792
Ward, Connor http://orcid.org/0000-0002-8949-7521
Schwartz, Rachel
Wilder-Romans, Kari
Liu, Meilan
Nino, Charles
Jungles, Kassidy http://orcid.org/0000-0001-5705-8455
Azaria, Ruth http://orcid.org/0000-0002-1686-2591
Jelley, Alexa
Zambrana Garcia, Nicole
Harold, Alexis
Zhang, Amanda
Wharram, Bryan
Hayes, Daniel F. http://orcid.org/0000-0003-3620-7575
Rae, James M.
Pierce, Lori J.
Speers, Corey W. http://orcid.org/0000-0002-2362-2860
Funding for this research was provided by:
generous donation from Susan and Richard Bayer
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32-GM113900, T32-GM007315, T32-GM007767, T32-GM007863, T32-GM007767)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
U-M | Horace H. Rackham School of Graduate Studies, University of Michigan
U.S. Department of Health & Human Services | NIH | National Cancer Institute (F31CA254138)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
Breast Cancer Research Foundation (BCRF-21-128)
Article History
Received: 27 September 2021
Accepted: 3 February 2022
First Online: 10 March 2022
Change Date: 20 April 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41523-022-00418-w
Competing interests
: The University of Michigan has received funding to support research on behalf of D.F.H. from AstraZeneca, manufacturer of fulvestrant. D.F.H. has stock options at InBiomotion and is a paid consultant/scientific advisory for Cepheid, Freenome, CellWorks, Lexent Bio, EPIC Science, Salutogenic Innovations, L-Nutra, BioVeca, OncoCyte, Turnstone Biologics, Predictus BioSciences, Tempus, Guardant. The University of Michigan has received funding to support research on behalf of D.F.H. from Merrimack, Eli Lilly, Menarini/Silicon Biosystems, Puma Biotechnology, Pfizer. The University of Michigan holds a patent on which D.F.H. is the named investigator and which is licensed to Menarini/Silicon Biosystems with annual royalties through January 2021. C.W.S. is a paid consultant of Exact Sciences. L.J.P. is a paid consultant for UpToDate and an unpaid consultant for Exact Sciences. The remaining authors declare no competing interests.